Oxygen Biotherapeutics (OXBT) reported last Tuesday, June 18th, that it had completed preclinical trials on animals evaluating its lead drug candidate, Oxycyte, for potential effects on the body's immune system. Oxycyte® is a perfluorocarbon-based intravenous oxygen carrier with multiple potential uses. Lead trials are focusing on the ability of the treatment to rapidly deliver oxygen to the patient's brain after a traumatic brain injury (TBI) to reduce acute damage and long-term complications. While news came out on the 18th, the company's stock action has been gradually responding with increasing liquidity and share price, although the overall markets have put a drag on share price this week. With a split-adjusted 52-week range of $2.53-$34.40, I believe Wednesday's closing share price...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|